Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Description

Members of the I-MOVE+ working group - Portugal: B. Nunes, A. Machado, A.P. Rodrigues, V. Gómez, I. Kislaya, R. Guiomar, P. Pechirra, P. Cristóvão, I. Costa (National Health Institute Doutor Ricardo Jorge, Lisbon), A.Panarra, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal).

Keywords

Influenza Vaccine Vacina Antigripal Determinantes da Saúde e da Doença Vaccine Effectiveness Cuidados de Saúde Europe Case control study Influenza Influenza Vaccination Influenza Vaccine Effectiveness Multicentre Study